When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
PRVB - Provention Bio up 176% premarket on potential of teplizumab to delay diabetes
Provention Bio Inc.
Thinly traded micro cap Provention Bio (NASDAQ:PRVB) rockets 176% premarket on robust volume in reaction to its announcement of positive trial data on lead candidate teplizumab (PRV-031), in Phase 3 development for the interception of type 1 diabetes (T1D). The results were presented at the American Diabetes Association Scientific Sessions in San Francisco.
More news on: Provention Bio, Inc., Healthcare stocks news, Stocks on the move,